Treatment Goals, Disease Control Targets, and the Role of Patient-Reported Outcome Measures

The Urticaria Activity Score over 7 days (UAS7) is the primary validated instrument for measuring CSU disease activity in clinical trials and forms the evidentiary foundation for interpreting treatment efficacy across all 3 agents now recommended in international guidelines. A score of 0 — the formal definition of complete response — requires 7 consecutive days free of both wheals and itch, making it a stringent and difficult-to-achieve endpoint. Even the most effective agents in the current therapeutic landscape fall short of producing a UAS7 of 0 in the majority of treated patients, a limitation the guidelines acknowledge while continuing to endorse complete control as the therapeutic aspiration. Patients who do not reach a UAS7 of 0 can still experience transformative improvement; some achieve scores in the range of 3 to 6 and report that their quality of life has been fundamentally restored, which argues for initiating therapy rather than withholding it in pursuit of a theoretically ideal outcome.

The Urticaria Control Test (UCT) offers a more pragmatic instrument for routine clinical practice, particularly in high-volume dermatology settings where prospective daily symptom tracking is impractical. Although neither tool is universally adopted across specialties, both serve an important documentation function in the current payer environment and should be familiar to prescribing clinicians. Payer requirements for prior authorization of biologic and targeted therapies in CSU are evolving, and maintaining dual assessment — UAS7 and UCT — as part of the intake process may be prudent until coverage criteria are more clearly standardized. A practical concern also exists regarding data quality: many patients complete the UAS7 from memory at clinic visits rather than prospectively, which may diminish the reliability of recorded scores.

In this video segment, Nicole Chase, MD, and Jason Hawkes, MD, converge on a pragmatic middle ground: formal scoring aside, what matters clinically is establishing a baseline sense of disease burden and tracking directional change over time. The expansion of the treatment armamentarium brings renewed relevance to the challenge of incomplete response. With 3 mechanistically distinct step-up agents now available, clinicians can more credibly reassure patients that falling short of complete control on 1 agent does not represent a therapeutic dead end — a reframing that carries particular value in a condition where psychological stress is itself a recognized disease trigger. Communicating realistic but optimistic expectations at the outset supports adherence and reduces the risk that patients disengage from care before meaningful benefit is achieved.